Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I

##STR00001##

wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R.sub.1 and R.sub.2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.

Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I

##STR00001##

wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R.sub.1 and R.sub.2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.

Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure: ##STR00001##

Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same. A preferred polymer has a repeating unit of the following structure: ##STR00001##

A glucosamine peptide compound or a pharmaceutically acceptable salt thereof are useful for treating liver metabolic disorders, wherein the glucosamine peptide compound may have the structure of Glc-L-Pep, and wherein Glc represents glucosamine moiety, L represents a linker, Pep represents a peptide moiety consisting of two to six amino acid residues, Glc and L are bonded by an ether linkage, and L and Pep are bonded by an amide linkage. The liver metabolic disorders include nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, alcoholic fatty liver disease, alcoholic steatohepatitis, hepatic steatosis, liver fibrosis, cirrhosis or a combination thereof.

A glucosamine peptide compound or a pharmaceutically acceptable salt thereof are useful for treating liver metabolic disorders, wherein the glucosamine peptide compound may have the structure of Glc-L-Pep, and wherein Glc represents glucosamine moiety, L represents a linker, Pep represents a peptide moiety consisting of two to six amino acid residues, Glc and L are bonded by an ether linkage, and L and Pep are bonded by an amide linkage. The liver metabolic disorders include nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, alcoholic fatty liver disease, alcoholic steatohepatitis, hepatic steatosis, liver fibrosis, cirrhosis or a combination thereof.

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.